Literature DB >> 10448297

Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma.

B Meister1, F Grünebach, F Bautz, W Brugger, F M Fink, L Kanz, R Möhle.   

Abstract

Angiogenic factors may play a role in the biology of neuroblastoma, a well vascularised tumour, which frequently spreads haematogenously. Therefore, we analysed expression of vascular endothelial growth factor (VEGF) in six human neuroblastoma cell lines and five primary neuroblastomas. High VEGF levels (1-3 ng/10(6) cells/day) were found in the supernatant of all cell lines examined (SK-N-LO, SK-N-SH, LS, SH-SY5Y, IMR-32, Kelly). VEGF peptide was also detected in tissue homogenates from four of five primary tumours. Reverse transcription-polymerase chain reaction (RT-PCR) revealed that VEGF165 is the major isoform produced by neuroblastomas. In addition, all cell lines and primary tumours expressed the mitogenic VEGF receptor FLK-1, whilst the non-mitogenic receptor FLT-1 was less frequently positive, suggesting that the tyrosine kinase FLK-1 is involved in malignant transformation of neuroblastoma cells. However, neutralising antibodies to VEGF did not inhibit growth of neuroblastoma cell lines, which argues against a role of VEGF as an autocrine growth factor, at least for cell lines in vitro. We conclude that neuroblastoma cells produce VEGF, which may contribute to tumour vascularisation, growth and invasion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448297     DOI: 10.1016/s0959-8049(98)00387-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  27 in total

1.  Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Authors:  Jürgen Becker; Helena Pavlakovic; Fabian Ludewig; Fabiola Wilting; Herbert A Weich; Romulo Albuquerque; Jayakrishna Ambati; Jörg Wilting
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  Modulation of VEGF/Flk-1 receptor expression in the rat pituitary GH3 cell line by growth factors.

Authors:  Matilde Lombardero; Sergio Vidal; Robert Hurta; Alba Román; Kalman Kovacs; Ricardo V Lloyd; Bernd W Scheithauer
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 3.  Cell survival signaling in neuroblastoma.

Authors:  Michael L Megison; Lauren A Gillory; Elizabeth A Beierle
Journal:  Anticancer Agents Med Chem       Date:  2013-05       Impact factor: 2.505

Review 4.  VEGF in brain tumors.

Authors:  M R Machein; K H Plate
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

5.  Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.

Authors:  Paola Bocca; Emma Di Carlo; Ignazio Caruana; Laura Emionite; Michele Cilli; Biagio De Angelis; Concetta Quintarelli; Annalisa Pezzolo; Lizzia Raffaghello; Fabio Morandi; Franco Locatelli; Vito Pistoia; Ignazia Prigione
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

6.  Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells.

Authors:  Caroline Muir; Leland W K Chung; Daniel D Carson; Mary C Farach-Carson
Journal:  Clin Exp Metastasis       Date:  2006-07-07       Impact factor: 5.150

7.  Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells.

Authors:  Hua Zhang; Jian Wu; Lin Meng; Cheng-Chao Shou
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

8.  UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.

Authors:  Peter E Zage; Natalie Sirisaengtaksin; Yin Liu; Monica Gireud; Brandon S Brown; Shana Palla; Kristen N Richards; Dennis P M Hughes; Andrew J Bean
Journal:  Cancer       Date:  2012-09-18       Impact factor: 6.860

9.  VEGF and Bcl-2 interact via MAPKs signaling pathway in the response to hypoxia in neuroblastoma.

Authors:  Duoduo Wang; Qinjie Weng; Lei Zhang; Qiaojun He; Bo Yang
Journal:  Cell Mol Neurobiol       Date:  2008-12-02       Impact factor: 5.046

Review 10.  More than the genes, the tumor microenvironment in neuroblastoma.

Authors:  Lucia Borriello; Robert C Seeger; Shahab Asgharzadeh; Yves A DeClerck
Journal:  Cancer Lett       Date:  2015-11-17       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.